TABLE 2.
Blood serum biomarkers of prediabetic volunteers treated with Eriomin® or Placebo daily supplements for 12 weeks.
| Variables | Placebo | Eriomin® | ||
|---|---|---|---|---|
| 0 week | 12°week | 0 week | 12°week | |
| Glucose, mg/dL | 103 ± 8 | 105 ± 12 | 106 ± 12 | 99.0* ± 11.0 |
| Insulin, μU/mL | 19.5 ± 8.2 | 18.4 ± 9.9 | 18.1 ± 8.9 | 17.7 ± 8.3 |
| HOMA‐IR | 4.97 ± 2.34 | 4.99 ± 3.47 | 4.53 ± 1.78 | 4.37 ± 1.88 |
| HbA1c, % | 5.86 ± 0.42 | 5.79 ± 0.47 | 6.01 ± 0.53 | 5.87 ± 0.48 |
| Total Cholesterol, mg/dL | 222 ± 55 | 222 ± 45 | 185 ± 33 | 185 ± 39 |
| LDL‐Cholesterol, mg/dL | 140 ± 40 | 141 ± 34 | 102 ± 31 | 101 ± 35 |
| HDL‐Cholesterol, mg/dL | 44.6 ± 10.2 | 43.7 ± 11.1 | 44.5 ± 8.5 | 43.8 ± 7.0 |
| Triglycerides, mg/dL | 167 ± 75 | 189 ± 75 | 165 ± 74 | 168 ± 65 |
| Glucagon‐like peptide‐1 (GLP1) ρg/mL | 7.96 ± 2.06 | 7.97 ± 1.82 | 8.15 ± 2.3 | 10.0* ± 2.2 |
| Glucagon, ρg/mL | 147 ± 13 | 142 ± 18 | 144 ± 17 | 130 ± 11 |
| Adiponectin, μg /mL | 18.5 ± 5.21 | 19.6 ± 4.8 | 18.1 ± 9.4 | 20.4 ± 6.4 |
| C Peptide, ρg/mL | 1779 ± 483 | 1743 ± 532 | 2290 ± 861 | 2009 ± 671 |
| hsCRP, mg/dL | 0.39 ± 0.25 | 0.32 ± 0.15 | 0.37 ± 0.22 | 0.33 ± 0.18 |
| IL‐6, ρg/mL | 7.62 ± 5.34 | 7.61 ± 6.14 | 5.86 ± 2.50 | 4.87 ± 1.74 |
| TNF‐α, ρg/mL | 5.45 ± 1.35 | 5.18 ± 1.75 | 5.66 ± 1.36 | 5.03 ± 1.51 |
| Antioxidant capacity, μM | 1.88 ± 0.04 | 1.89 ± 0.03 | 1.86 ± 0.10 | 1.90 ± 0.03 |
| Lipid peroxidation (MDA) mM | 2.25 ± 1.22 | 2.05 ± 1.21 | 1.60 ± 0.76 | 1.49 ± 0.68 |
| Alkaline phosphatase (ALP) U/L | 67.3 ± 12.1 | 67.3 ± 18.0 | 57.6 ± 13.2 | 57.3 ± 14.5 |
| γ‐glutamyl transferase (γGT), U/L | 57.2 ± 34.8 | 68.3* ±37.0 | 38.8 ± 32.4 | 39.2 ± 29.0 |
| Aspartate transaminase (AST), U/L | 26.6b ± 8.2 | 29.9b ± 8.0 | 19.4a ± 4.0 | 21.1a ± 4.5 |
| Alanine transaminase (ALT), U/L | 35.3b ± 17.4 | 40.1b ± 14.9 | 20.2a ± 6.3 | 22.4a ± 8.3 |
| Urea, mg/dL | 31.5 ± 8.7 | 32.5 ± 9.4 | 34.2 ± 15.0 | 32.3 ± 9.0 |
| Creatinine, mg/dL | 0.90 ± 0.15 | 0.92 ± 0.23 | 0.85 ± 0.29 | 0.86 ± 0.21 |
Note: Data are presented as mean ± SD. Statistical analysis: Two‐way ANOVA on Ranks, followed by Holm–Sidak to detect changes in intragroup (week 0 vs. week 12) and intergroups (Placebo vs. Eriomin).
*
Statistical difference significant intragroup (week 0 vs. week 12) (p ≤ .05).
a ≠ b Statistical difference significant intergroups (Eriomin vs. Placebo) (p ≤ .05).